TABLE 3.
Summary of ΔΔQTcF at each time point on Day 7.
| Time, h | ΔΔQTcF, LS mean (90% CI), ms | ||
|---|---|---|---|
| GSK'254 100 mg | GSK'254 500 mg | Moxifloxacin 400 mg | |
| Pre‐dose | 1.4 (−0.88, 3.77) | 7.1 (4.74, 9.46) | 0.6 (−1.74, 2.90) |
| 0.5 | 1.0 (−1.60, 3.59) | 7.2 (4.59, 9.83) | −0.2 (−2.82, 2.37) |
| 1 | 0.6 (−2.06, 3.33) | 4.1 (1.34, 6.79) | −0.8 (−3.50, 1.88) |
| 2 | 1.7 (−1.27, 4.73) | 6.5 (3.46, 9.55) | 5.6 (2.57, 8.61) |
| 3 | 1.5 (−1.45, 4.51) | 8.1 (5.06, 11.09) | 7.9 (4.94, 10.92) |
| 3.5 | 1.4 (−1.30, 4.13) | 9.2 (6.44, 11.93) | 8.9 (6.15, 11.60) |
| 4 | 1.0 (−1.59, 3.54) | 8.6 (6.03, 11.22) | 8.6 (6.07, 11.21) |
| 4.5 | 1.0 (−1.73, 3.82) | 10.6 (7.75, 13.38) | 8.4 (5.62, 11.18) |
| 5 | 0.2 (−2.44, 2.80) | 9.6 (6.92, 12.24) | 8.2 (5.53, 10.79) |
| 6 | 1.7 (−1.58, 4.97) | 8.6 (5.27, 11.89) | 8.2 (4.94, 11.50) |
| 8 | −0.8 (−3.54, 1.90) | 8.1 (5.34, 10.85) | 6.9 (4.19, 9.66) |
| 10 | 0.2 (−2.30, 2.65) | 8.6 (6.14, 11.15) | 6.8 (4.30, 9.28) |
| 12 | 0.5 (−2.43, 3.35) | 6.0 (3.07, 8.89) | 5.3 (2.38, 8.17) |
| 24 | 0.1 (−2.66, 2.76) | 7.7 (4.94, 10.45) | 6.8 (4.13, 9.54) |
Abbreviations: GSK'254, GSK3640254; LS, least‐squares; QTcF, QT interval corrected using Fridericia's formula; ΔΔQTcF, placebo‐adjusted change from baseline in QTcF.